Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV – A systematic review and network meta-analysis of randomized controlled trials

Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP.